Biogen
BIIB
945 hedge funds and large institutions have $29.9B invested in Biogen in 2024 Q2 according to their latest regulatory filings, with 102 funds opening new positions, 322 increasing their positions, 337 reducing their positions, and 97 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
5% more first-time investments, than exits
New positions opened: 102 | Existing positions closed: 97
0.65% less ownership
Funds ownership: 89.26% → 88.6% (-0.65%)
4% less capital inflows, than outflows
Capital inflows: $1.69B | Capital outflows: $1.77B
4% less repeat investments, than reductions
Existing positions increased: 322 | Existing positions reduced: 337
10% less call options, than puts
Call options by funds: $318M | Put options by funds: $353M
1% less funds holding
Funds holding: 955 → 945 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$142M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$121M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$111M |
| 4 |
Goldman Sachs
New York
|
+$92.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$91.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
-$177M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$87.8M |
| 3 |
Camber Capital Management
Boston,
Massachusetts
|
-$86.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$82.3M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$73.8M |
BIIB Hedge Fund Activity: Q2 2024 in Review
945 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2024, worth a combined $29.9B — up 6.9% from $28B a quarter earlier.
Buyers outnumbered sellers: 102 funds opened new BIIB positions and 97 closed out — a net gain of 5 holders — while 322 added to existing stakes and 337 trimmed.
The largest buyer was Ameriprise, adding an estimated $142M. The largest seller was VanEck Associates, cutting an estimated $177M.
- 945 institutional investors held Biogen (BIIB) as of Q2 2024, down from 955 in Q1 2024.
- Funds reported $29.9B of Biogen stock for Q2 2024, up 6.9% quarter-over-quarter.
- 102 funds opened new Biogen positions in Q2 2024 and 97 closed out, a net change of +5 holders.
- The largest Biogen buyer in Q2 2024 was Ameriprise, an estimated $142M added.
- The largest Biogen seller in Q2 2024 was VanEck Associates, an estimated $177M sold.
Based on aggregated 13F filings for Q2 2024.